European Committee on Antimicrobial Susceptibility Testing

Recommendations

Info

Pseudomonas spp. EUCAST Clinical Breakpoint Tables v. 7.0, valid from 2017-01-01 Fluoroquinolones MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Ciprofloxacin 1 0.5 0.5 5 26 26 Levofloxacin 2 1 1 5 22 22 Moxifloxacin - - - - Nalidixic acid (screen) NA NA NA NA Norfloxacin (uncomplicated UTI only) - - - - Ofloxacin - - - - Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 1. Breakpoints are based on high dose therapy (0.75 g x 2 oral or 0.4 g x 3 iv). 2. Breakpoints are based on high dose therapy (0.5 g x 2 oral or 0.5 g x 2 iv). Aminoglycosides 1 MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Amikacin 8 16 30 18 15 Gentamicin 4 4 10 15 15 Netilmicin 4 4 10 12 12 Tobramycin 4 4 10 16 16 Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 1. Aminoglycoside breakpoints are based on once-daily administration of high aminoglycoside dosages. Most often aminoglycosides are given in combination with beta-lactam agents. Glycopeptides and lipoglycopeptides MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Dalbavancin - - - - Oritavancin - - - - Teicoplanin - - - - Telavancin - - - - Vancomycin - - - - Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Macrolides, lincosamides and streptogramins MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Azithromycin - - - - Clarithromycin - - - - Erythromycin - - - - Roxithromycin - - - - Telithromycin - - - - Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Clindamycin - - - - Quinupristin-dalfopristin - - - - 13
Pseudomonas spp. EUCAST Clinical Breakpoint Tables v. 7.0, valid from 2017-01-01 Tetracyclines MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Doxycycline - - - - Minocycline - - - - Tetracycline - - - - Tigecycline - - - - Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Oxazolidinones MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Linezolid - - - - Tedizolid - - - - A. Zone diameter breakpoints validated for E. coli only. For other Enterobacteriaceae, use an MIC method. Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Miscellaneous agents (µg) (mm) S ≤ R > S ≥ R < Chloramphenicol - - - - Colistin 1 2 2 Note A Note A Daptomycin - - - - Fosfomycin iv 2 - - - - Fosfomycin oral 2 - - - - Fusidic acid - - - - Metronidazole - - - - Mupirocin MIC breakpoint (mg/L) Disk content Zone diameter breakpoint Nitrofurantoin (uncomplicated UTI only) - - - - Nitroxoline (uncomplicated UTI only) - - - - Rifampicin - - - - Spectinomycin - - - - Trimethoprim (uncomplicated UTI only) - - - - Trimethoprim-sulfamethoxazole - - - - Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 1. Quality control of colistin must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). 2. Infections caused by wild type isolates (ECOFF 128 mg/L) have been treated with combinations of fosfomycin and other agents. A. Use an MIC method. 14
Page 1 and 2: European C
Page 3 and 4: Guidance on reading EUCAST Breakpoi
Page 5 and 6: Version 7.0, 2017-01-01 Acinetobact
Page 7 and 8: Enterobacteriaceae EUCAST Clinical
Page 13: Pseudomonas spp. EUCAST Clinical Br
Page 17 and 18: Acinetobacter spp. EUCAST Clinical
Page 19 and 20: Acinetobacter spp. EUCAST Clinical
Page 21 and 22: Staphylococcus spp. EUCAST Clinical
Page 27 and 28: Enterococcus spp. EUCAST Clinical B
Page 29 and 30: Enterococcus spp. EUCAST Clinical B
Page 31 and 32: Streptococcus groups A, B, C and G
Page 37 and 38: Streptococcus pneumoniae EUCAST Cli
Page 43 and 44: Viridans group streptococci EUCAST
Page 45 and 46: Viridans group streptococci EUCAST
Page 47 and 48: Haemophilus influenzae EUCAST Clini
Page 53 and 54: Moraxella catarrhalis EUCAST Clinic
Page 55 and 56: Moraxella catarrhalis EUCAST Clinic
Page 57 and 58: Neisseria gonorrhoeae EUCAST Clinic
Page 59 and 60: Neisseria gonorrhoeae EUCAST Clinic
Page 61 and 62: Neisseria meningitidis EUCAST Clini
Page 63 and 64: Neisseria meningitidis EUCAST Clini
Page 65 and 66:
Gram-positive anaerobes except Clos
Page 67 and 68:
Gram-positive anaerobes except Clos
Page 69 and 70:
Clostridium difficile EUCAST Clinic
Page 71 and 72:
Gram-negative anaerobes EUCAST Clin
Page 73 and 74:
Gram-negative anaerobes EUCAST Clin
Page 75 and 76:
Listeria monocytogenes EUCAST Clini
Page 77 and 78:
Pasteurella multocida EUCAST Clinic
Page 79 and 80:
Corynebacterium spp. EUCAST Clinica
Page 81 and 82:
Aerococcus sanguinicola and urinae
Page 83 and 84:
Kingella kingae EUCAST Clinical Bre
Page 85 and 86:
Mycobacterium tuberculosis EUCAST C
Page 87 and 88:
PK/PD (Non-species related) breakpo
Page 89 and 90:
PK/PD (Non-species related) breakpo
Page 91 and 92:
Dosages EUCAST Clinical Breakpoint
Page 93 and 94:
Dosages EUCAST Clinical Breakpoint
show all

European Committee on Antimicrobial Susceptibility Testing

Create successful ePaper yourself

Delete template?

Save as template?